UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics leads the fight against hyperphosphatemia in kidney disease with two breakthrough therapies, offering safer, more effective options for patients and investors alike.

Unicycive Therapeutics advances novel hyperphosphatemia treatments for CKD and AKI, aiming to curb complications and attract investors with a promising pipeline.

Unicycive Therapeutics advances its hyperphosphatemia therapy, targeting chronic kidney disease patients, and sets a key FDA review date to drive future growth.

Unicycive Therapeutics files S‑3, becomes Nasdaq‑listed, and boosts CEO‑CFO RSUs while advancing kidney‑care therapies, aiming for breakthrough growth.

Unicycive Therapeutics: Pioneering hyperphosphatemia treatments for CKD & AKI patients, driving innovative kidney care while navigating biotech growth challenges.

Unicycive Therapeutics’ stock climbs after a standout Needham conference, boosting investor confidence and highlighting its pioneering kidney‑health therapies.

Unicycive Therapeutics faces a critical juncture after a director’s resignation and volatile stock, prompting investors to scrutinize its financial health and kidney‑disease therapy pipeline for sustainable growth.

Unicycive Therapeutics sees analyst downgrade: Guggenheim cuts target price after reassessment, prompting investors to re‑evaluate its kidney‑care drug pipeline.

Unicycive Therapeutics reports Q4 2025 results: a $0.82 per-share loss, narrowing from $2.60 last year, and near‑break‑even full‑year EPS of $1.67.

Unicycive Therapeutics: No new developments or financial updates, only current fundamentals remain unchanged.